RxDoctor Payments Data

Priyanka Batchu, MD

Cardiovascular Disease · Cherry Hill, NJNPI 1649638586

Payments from drug & device makers

$3,144in general payments, 2019–2025

Across 128 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$595
  • Abbott$486
  • Novartis$238
  • AstraZeneca$221
  • Amgen$192
  • Impulse Dynamics (USA) Inc.$173
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,54881%
  • Education$51216%
  • Gifts$843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,144 in reported general payments places this provider in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$105,701
Medicare patients
661
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$44,660
FarxigaDapagliflozin Propanediol12$11,217
Metoprolol Tartrate17$1,057
Atorvastatin Calcium56$1,008
Metoprolol Succinate60$697
Rosuvastatin Calcium13$487
Carvedilol26$285
Valsartan11$280
Amlodipine Besylate35$262
Furosemide30$234
Losartan Potassium16$166
Isosorbide Mononitrate ErIsosorbide Mononitrate13$122
ClopidogrelClopidogrel Bisulfate11$92
Lisinopril11$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$44,66040 claims
AstraZenecaFarxiga$221$11,21712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →